Free public records show Exela Pharma in 2 of the markets we cover. It is not a key player in our research.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
12 approvals with a product on the US market
Source: Drugs@FDA, Approvals (NDA, ANDA, BLA) held, with a product sold now; newest shown. Retrieved 13 Nov 2026.
12 recalls since 2015 (12 for medicines)
Source: openFDA, FDA enforcement reports (recalls) naming the firm, since 2015. Retrieved 13 Nov 2026.
Markets we cover where free public records show Exela Pharma: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets Exela Pharma is in.
Stories on the topics Exela Pharma works in.
1.71 billion people live with musculoskeletal conditions, including 528 million with osteoarthritis. Evidence…
Read
2.2 billion people have a vision impairment. One supplement formula has strong trial evidence, but only for a…
Read
170 of 194 WHO member states report use of traditional medicine. Herbal products are popular, but quality and…
Read